Serogroup A meningococcal conjugate vaccines in Africa

References

• Lapeyssonnie L. La méningite cérébrospinale en Afrique [in French]. Bull World Health Organ 1963;28:3-114
   Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27:B51-63
   PubMed Web of Science ®Google Scholar
• Mohammed I, Nasidi A, Alkali AS, et al. A severe epidemic of meningococcal meningitis in Nigeria, 1996. Trans R Soc Trop Med Hyg 2000;94:265-70
   PubMed Web of Science ®Google Scholar
• Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93:341-53
   PubMed Web of Science ®Google Scholar
• Broome CV, Rugh MA, Yada AA, et al. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Organ 1983;61:325-30
   PubMed Web of Science ®Google Scholar
• Whittle HC, Greenwood BM. Meningococcal meningitis in the northern savanna of Africa. Trop Doct 1976;6:99-104
   PubMedGoogle Scholar
• Koumaré B, Ouedraogo-Traoré R, Sanou I, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine 2007;25:A37-41
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63
   PubMed Web of Science ®Google Scholar
• Materu S, Cox HS, Isaakidis P, et al. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 2007;13:944-5
   PubMed Web of Science ®Google Scholar
• Caugant DA, Maiden MC. Meningococcal carriage and disease - population biology and evolution. Vaccine 2009;27(Suppl 2):B64-70
   PubMed Web of Science ®Google Scholar
• Caugant DA, Kristiansen PA, Wang X, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012;7:e46019
   PubMed Web of Science ®Google Scholar
• Nicolas P, Norheim G, Garnotel E, et al. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35
   PubMed Web of Science ®Google Scholar
• Smith PG. Concepts of herd protection and immunity. Procedia Vaccinol 2010;2:134-9
   Google Scholar
• Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programmes. Expert Rev Vaccines 2009;8:851-61
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367-84
   PubMed Web of Science ®Google Scholar
• Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med 1970;282:417-20
   PubMed Web of Science ®Google Scholar
• Wahdan MH, Rizk F, el-Akkad AM, et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ 1973;48:667-73
   PubMed Web of Science ®Google Scholar
• Makela PH, Kaythy H, Weckstrom P, et al. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 1975;8:883-6
   Google Scholar
• Erwa HH, Haseeb MA, Idris AA, et al. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull World Health Organ 1973;49:302-5
   Web of Science ®Google Scholar
• Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 1982;37:205-8
   PubMed Web of Science ®Google Scholar
• MacLennan CA. Vaccines for low-income countries. Semin Immunol 2013;25:114-23
   PubMed Web of Science ®Google Scholar
• WHO. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition World Health Organization; Geneva: 1998
   Google Scholar
• Lewis R, Nathan N, Diarra L, et al. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001;358:287-93
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarro M, Toe L, Tiendrebeogo SR, et al. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine 2007;25(Suppl 1):A92-6
   PubMed Web of Science ®Google Scholar
• Chandramohan D, Hodgson A, Coleman P, et al. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. Vaccine 2007;25(Suppl 1):A83-91
   PubMed Web of Science ®Google Scholar
• Aseffa A, Bedru A, Yamuah L, et al. Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. Vaccine 2007;25(Suppl 1):A79-82
   PubMed Web of Science ®Google Scholar
• Ada G, Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 2003;9:79-85
   PubMed Web of Science ®Google Scholar
• Twumasi PAJr, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171:632-8
   PubMed Web of Science ®Google Scholar
• Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999;17:3086-93
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001;183:97-104
   PubMed Web of Science ®Google Scholar
• Campagne G, Garba A, Fabre P, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000;19:144-50
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Garba A, Ethevenaux C, et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 2004;22:3303-11
   PubMed Web of Science ®Google Scholar
• Hodgson A, Forgor AA, Chandramohan D, et al. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 2008;3:e2159
   PubMed Web of Science ®Google Scholar
• LaForce FM, Konde K, Viviani S, Preziosi MP. The meningitis vaccine project. Vaccine 2007;25:A97-A100
   PubMed Web of Science ®Google Scholar
• Report of the strategic advisory group of experts (SAGE), Geneva, 14-15 June 2001. WHO. Available from: http://whqlibdoc.who.int/hq/2002/WHO_V&B_02.07.pdf [Last accessed 12 June 2015]
   Google Scholar
• Bishai DM, Champion C, Steele ME, Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood) 2011;30:1058-64
   PubMed Web of Science ®Google Scholar
• Jodar L, LaForce FM, Ceccarini C, et al. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003;361:1902-4
   PubMed Web of Science ®Google Scholar
• Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVacTM. Hum Vaccin Immunother 2012;8:715-24
   PubMed Web of Science ®Google Scholar
• Lee CH, Kuo WC, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009;27:726-32
   PubMed Web of Science ®Google Scholar
• Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007;25:A101-7
   PubMed Web of Science ®Google Scholar
• Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364:2293-304
   PubMed Web of Science ®Google Scholar
• Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine 2012;30:6456-60
   PubMed Web of Science ®Google Scholar
• Steffen C, Tokplonou E, Jaillard P, et al. A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin. Pan Afr Med J 2014;18:344
   PubMedGoogle Scholar
• Results from the MenA conjugate vaccine (PsA-TT) randomized controlled trials in infants and young children. Executive summary. SAGE, October 2014. Available from: www.who.int/immunization/sage/meetings/2014/october/3_MenA_vaccine_trials_SAGE_01Oct2014.pdf [Last accessed 12 June 2015]
   Google Scholar
• Meningococcal a conjugate vaccine lyophilized MenAfriVac. Available from: www.seruminstitute.com/content/products/product_menafrivac.htm
   Google Scholar
• Technical Note. MenAfriVacTM vaccine campaigns in the African meningitis belt. Use of vaccine in pregnant and lactating women. 22 November 2010. Available from: www.who.int/immunization/sage/4_WHO_Note_Vaccination__Pregnant_Women__during_MenA__conj_Campaigns_22Nov10_april_2011.pdf [Last accessed 12 June 2015]
   Google Scholar
• Weekly epidemiological record. Relevé épidémiologique hebdomadaire. Available from: www.who.int/wer/2014/wer8921.pdf?ua=1
   Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B112-16
   PubMed Web of Science ®Google Scholar
• Jodar L, Cartwright K, Feavers IM. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 2000;28:193-7
   PubMedGoogle Scholar
• Bash MC, Lynn F, Mocca B, et al. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers. Clin Vaccine Immunol 2014;21:755-61
   PubMed Web of Science ®Google Scholar
• Basta N, Ng S, Berthe A, et al. Meningococcal serogroup A and tetanus immunity two years after MenAfriVacTM introduction in Mali. In: 16th International Congress on Infectious Diseases. Cape Town, South Africa; 2014; Abstract number 63.012
   Google Scholar
• Evaluation of the antibody persistence in African subjects up to five years after immunization with MenAfriVac, a meningococcal A conjugate vaccine. Available from: www.meningvax.com/clinical-persistence.php
   Google Scholar
• Meningococcal A conjugate 10 dose presentation. Available from: www.who.int/immunization_standards/vaccine_quality/PQ_197_MenAconjugate_10dose_SII/en/
   Google Scholar
• Prequalification of medicines by WHO. Available from: www.who.int/mediacentre/factsheets/fs278/en/
   Google Scholar
• WHO grants approval for safe, effective meningitis A vaccine for infants. Available from: www.who.int/immunization/newsroom/press/9_01_2015_meningitis_vaccine_who_approval/en/
   Google Scholar
• Zipursky S, Djingarey MH, Lodjo JC, et al. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014;32:1431-5
   PubMed Web of Science ®Google Scholar
• MVP news digest. Available from: www.meningvax.org/newsletters.php [last accessed 12 June 2015]
   Google Scholar
• MERIT Strategic review meeting synthesis report. Available from: www.wmo.int/pages/prog/arep/wwrp/new/documents/3_9_2_MERIT_Strategic_Review.pdf
   Google Scholar
• Maiden MCJ, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-30
   PubMed Web of Science ®Google Scholar
• Bijlsma MW, Brouwer MC, Spanjaard L, et al. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination. Clin Infect Dis 2014;59:1216-21
   PubMed Web of Science ®Google Scholar
• Chaibou MS, Bako H, Salisou L, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine 2012;30:5229-34
   PubMed Web of Science ®Google Scholar
• Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012;30 Suppl 2:B40-5
   PubMed Web of Science ®Google Scholar
• Ouandaogo CR, Yameogo TM, Diomande FVK, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 2012;30(Suppl 2):B46-51
   PubMed Web of Science ®Google Scholar
• Weekly Epidemiological Record. WHO. Available from: www.who.int/wer [Last accessed 12 June 2015]
   Google Scholar
• Republic of Chad State Office Ministry of Public Health. Available from: www.meningvax.org/files/2ndstatementMoHChad_21Jan2013.pdf
   Google Scholar
• Kristiansen PA, Misegades L, Absatou KB, et al. Factors affecting vaccine uptake during mass-vaccination with the serogroup A meningococcal conjugate vaccine, MenAfriVac in Burkina Faso. In: 19th International Pathogenic Neisseria Conference. Asheville; 2014. p. P103
   Google Scholar
• Meyer SA, Kambou JL, Cohn A, et al. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso - Implications for introduction of PsA-TT into the Expanded Programme on Immunization. Vaccine 2015;33:1492-8
   PubMed Web of Science ®Google Scholar
• Caini S, Beck NS, Yacouba H, et al. From Agadez to Zinder: estimating coverage of the MenAfriVac conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012. Vaccine 2013;31:1597-603
   PubMed Web of Science ®Google Scholar
• Mueller JE. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. Trop Med Int Health 2013;18:58-64
   PubMed Web of Science ®Google Scholar
• CDC. Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine - Burkina Faso and Mali. Morb Mortal Wkly Rep 2012;61:1025-8
   PubMedGoogle Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet 2014;383:40-7
   PubMed Web of Science ®Google Scholar
• Novak RT, Kambou JL, Diomande FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012;12:757-64
   PubMed Web of Science ®Google Scholar
• Ouangraoua S, Schlumberger M, Yaro S, et al. Impact of a conjugated anti-meningococcal A vaccine on notification of bacterial meningitis in West Burkina Faso (2009-2012). Bull Soc Pathol Exot 2014;107:27-30
   PubMedGoogle Scholar
• Agbenoko K, Moisi J, Makawa MS, et al. A period of low meningococcal meningitis incidence in northern Togo in absence of MenAfriVac. In: 18th International Pathogenic Neisseria Conference. Würzburg, Germany; 2012. p. P186
   Google Scholar
• Collard JM, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013;13:576
   PubMed Web of Science ®Google Scholar
• Gamougam K, Daugla DM, Toralta J, et al. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013. Emerg Infect Dis 2015;21:115-18
   PubMed Web of Science ®Google Scholar
• Meningitis outbreak response in sub-Saharan Africa - WHO guideline. WHO. Available from: www.who.int/csr/resources/publications/meningitis/guidelines2014/en/2014 [Last accessed 12 june 2015]
   Google Scholar
• Kristiansen PA, Diomandé F, Absatou KB, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56:354-63
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomande F, Wei SC, et al. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol 2011;18:435-43
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Ba AK, Ouedraogo AS, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine. MenAfriVac. BMC Infect Dis 2014;14:663
   PubMed Web of Science ®Google Scholar
• Farrington CP. On vaccine efficacy and reproduction numbers. Math Biosci 2003;185:89-109
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005;162:89-100
   PubMed Web of Science ®Google Scholar
• Tartof S, Cohn A, Tarbangdo F, et al. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One 2013;8:e63605
   PubMed Web of Science ®Google Scholar
• Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-6
   PubMed Web of Science ®Google Scholar
• Lancellotti M, Guiyoule A, Ruckly C, et al. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 2006;8:191-6
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Ba AK, Sanou I, et al. Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup A conjugate vaccine. BMC Infect Dis 2013;13:363
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non- pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-54
   PubMed Web of Science ®Google Scholar
• Scott JR, Millar EV, Lipsitch M, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities. J Infect Dis 2012;205:280-8
   PubMed Web of Science ®Google Scholar
• Hill PC, Akisanya A, Sankareh K, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis 2006;43:673-9
   PubMed Web of Science ®Google Scholar
• Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007;31:52-63
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Medah I, Koussoube D, et al. Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis 2014;20:394-9
   PubMed Web of Science ®Google Scholar
• Collard JM, Maman Z, Yacouba H, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 2010;16:1496-8
   PubMed Web of Science ®Google Scholar
• Hossain MJ, Roca A, Mackenzie GA, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis 2013;19:1507-10
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Barboza P, Taha MK. W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. EuroSurveill 2012;17(21):pii: 20181
   Web of Science ®Google Scholar
• Taha MK, Kacou-N’douba A, Hong E, et al. Travel-related Neisseria meningitidis serogroup W135 infection. France Emerg Infect Dis 2013;19:1030-2
   PubMed Web of Science ®Google Scholar
• Funk A, Uadiale K, Kamau C, et al. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Curr 2014;6
   PubMedGoogle Scholar
• WHO Meningitis weekly bulletin. WHO/inter country support team West Africa. Available from: www.who.int/csr/disease/meningococcal/epidemiological/en [Last accessed 12 June 2015]
   Google Scholar
• Carod Artal FJ. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt. Int Health 2015; Epud ahead of print
   PubMed Web of Science ®Google Scholar
• Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013;31:2852-61
   PubMed Web of Science ®Google Scholar
• Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA 2013;110:19077-82
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane AE, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 2013;31:1113-16
   PubMed Web of Science ®Google Scholar
• Tunheim G, Arnemo M, Naess LM, et al. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines. Vaccine 2013;31:6097-106
   PubMed Web of Science ®Google Scholar
• Tunheim G, Naess LM, Acevedo R, et al. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt. Vaccine 2014;32:6631-8
   PubMed Web of Science ®Google Scholar
• Ispasanie E, Pluschke G, Hodgson A, et al. Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009. F1000Res 2014;3:264
   PubMedGoogle Scholar
• Koeberling O, Ispasanie E, Hauser J, et al. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). Vaccine 2014;32:2688-95
   PubMed Web of Science ®Google Scholar
• A Phase III, double-blind, randomized, active controlled study to evaluate the safety and consistency of immunogenicity of three consecutive lots of a meningococcal A conjugate vaccine administered as a single dose to healthy children at 5–10 years of age. Available from: www.meningvax.org/clinical-005.php
   Google Scholar
• Evaluation of the antibody persistence in African subjects up to 5 years after immunization with MenAfriVac, a meningococcal A conjugate vaccine. Available from: www.meningvax.org/clinical-persistence.php
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. Morb Mortal Wkly Rep 2012;61:1022-4
   PubMedGoogle Scholar
• Kambou JL, Medah I, Yelbeogo D, et al. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign - Burkina Faso, 2011. Wkly Epidemiol Rec 2012;61:1022-4
   Google Scholar
• Kim SH, Pezzoli L, Yacouba H, et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One 2012;7:e29116
   PubMed Web of Science ®Google Scholar
• MCHIP Contributes in effort to tighten the ‘meningitis belt’: MenAfriVac campaign in senegal. Available from: www.mchip.net/node/1361
   Google Scholar
• Epidemiological information. Available from: www.who.int/csr/disease/meningococcal/epidemiological/en/
   Google Scholar